Aptinyx enters $50 million loan facility with K2 HealthVentures

By Marisa Wong

Los Angeles, Sept. 16 – Aptinyx Inc. entered into a $50 million loan facility and security agreement with K2 HealthVentures, according to a news release.

Aptinyx will receive $15 million after execution of the loan agreement, with an option to draw down an additional $10 million, which will support the future clinical development of multiple pipeline programs.

Under the terms of the agreement, the remaining $25 million is subject to the achievement of some terms and conditions, including regulatory and developmental milestones.

The Evanston, Ill.-based clinical stage biopharmaceutical company develops therapies for the treatment of brain and nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.